Cendakimab fell short of the bar. The antibody hits IL-13, one of the interleukins targeted by Regeneron and Sanofi’s ...
After winning a breakthrough therapy designation for its Hunter syndrome enzyme replacement therapy, Denali Therapeutics is ...
Novo Nordisk has bolstered the case for its near-approval hemophilia A drug candidate Mim8, linking the prospect to ...
Eye-disease-focused Acelyrin will be absorbed into immune-mediated disease specialist Alumis as part of an all-stock merger.
After parting ways with its diabetes franchise nearly three years ago, BD is slimming down even further with a plan to divest ...
After China placed Illumina on a government watchlist this week, in response to new tariffs imposed by the Trump ...
Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...
Cystic-fibrosis-focused Sionna Therapeutics is joining the Nasdaq this morning with an upsized public offering, while obesity ...
Genesis announced that it has completed its second successful human transplant with a genetically engineered pig kidney, with ...
Breakthrough research and investor enthusiasm prompted Cullinan Therapeutics to redirect one of its cancer programs toward ...
After their advanced kidney tumors were surgically removed, nine patients were protected from the cancer returning thanks to ...
Relmada, which has turned to strategic options after scrapping two phase 3 trials in major depressive disorder (MDD), is ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results